CASE STUDY: Portfolio strategy
CASE STUDY:
For this small venture capital-backed biotech, we identified and prioritized a list of targets that would diversify their portfolio across various disease areas.
CLIENT SITUATION:
- Client is a small venture capital-backed biotech
- Client needed to identify what near-term research programs they should pursue that leveraged their proprietary technology
- Goal was to conduct a structured, data-driven prioritization process that built a portfolio of development candidates that would be attractive to potential partners
TRINITY'S ROLE:
- Trinity conducted a multi-stage project that resulted in 7 lead research programs for the biotech to consider
- Identified an initial list of biological targets (eg, enzymes, receptors) amenable to the client’s technology
- Matched targets to clinically relevant indications; indications were then ranked by commercial potential and R&D “fit”
- Top indications were then “flipped” back to their target, and product concepts were generated for these prioritized targets
- Product concepts were validated by KOL interviews and additional research
- Prioritized targets and strategic options were presented to the client
ILLUSTRATIVE EXAMPLES:
Prioritization of indications
Indications grouped according to commercial opportunity and R&D feasibility
Strategic recommendations
Therapeutic area influenced the strategic opportunity for each target
PROJECT OUTCOMES:
The prioritized targets afforded a diversified portfolio across disease areas, in addition to a range of partnering and commercialization opportunities
- Biotech’s BoD decided to concentrate initial R&D efforts on four of the targets that Trinity identified